BioCentury
ARTICLE | Clinical News

HGSI begins Repifermin Phase II

September 4, 2001 7:00 AM UTC

Human Genome (HGSI) began a Phase II trial of Repifermin to treat mucositis in patients undergoing chemotherapy for multiple myeloma prior to autologous hematopoeitic stem cell transplantation. The 80...